Patients diagnosed with unresectable stage III non-small-cell lung cancer (NSCLC) typically receive concurrent chemoradiotherapy (CRT) followed by consolidation therapy with the anti-PD-L1 antibody durvalumab. Nonetheless, data from several studies suggest that patients with driver mutation-positive tumours often derive limited benefit from this approach. Now, data from the phase III LAURA trial demonstrate the efficacy of osimertinib following CRT in patients with stage III EGFR-mutant NSCLC.

A total of 216 patients without disease progression after completion of standard-of-care CRT were randomly assigned (2:1) to receive osimertinib or placebo. Eligible patients had to have at least one EGFR exon 19 deletion or L858R in exon 21. Progression-free survival (PFS) was the primary end point.

诊断为不可切除的 III 期非小细胞肺癌 （NSCLC） 患者通常同时接受放化疗 （CRT），然后接受抗 PD-L1 抗体 durvalumab 的巩固治疗。尽管如此，来自几项研究的数据表明，驱动基因突变阳性肿瘤患者通常从这种方法中获得的益处有限。现在，来自 III 期 LAURA 试验的数据表明，CRT 后奥希替尼对 III 期 EGFR 突变 NSCLC 患者的疗效。

共有 216 例在完成标准护理 CRT 后无疾病进展的患者被随机分配 （2：1） 接受奥希替尼或安慰剂。符合条件的患者必须至少有一个 EGFR 外显子 19 缺失或外显子 21 中有 L858R。无进展生存期 （PFS） 是主要终点。